Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.
Identifieur interne : 000296 ( Main/Exploration ); précédent : 000295; suivant : 000297Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.
Auteurs : Victoria Birlutiu ; Rares Mircea Birlutiu ; Liana Chicea [Roumanie]Source :
- Medicine [ 1536-5964 ] ; 2021.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Agents chélateurs du fer (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Association de médicaments (MeSH), Comorbidité (MeSH), Déférasirox (usage thérapeutique), Femelle (MeSH), Humains (MeSH), Mâle (MeSH), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Roumanie (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Utilisation hors indication (MeSH), Ventilation artificielle (MeSH), Études rétrospectives (MeSH).
- MESH :
- traitement médicamenteux : Pneumopathie virale.
- usage thérapeutique : Agents chélateurs du fer, Anticorps monoclonaux humanisés, Déférasirox.
- virologie : Pneumopathie virale.
- Adulte, Adulte d'âge moyen, Association de médicaments, Comorbidité, Femelle, Humains, Mâle, Roumanie, Sujet âgé, Sujet âgé de 80 ans ou plus, Utilisation hors indication, Ventilation artificielle, Études rétrospectives.
- Wicri :
- geographic : Roumanie.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antibodies, Monoclonal, Humanized (therapeutic use), COVID-19 (drug therapy), Comorbidity (MeSH), Cytokine Release Syndrome (drug therapy), Deferasirox (therapeutic use), Drug Therapy, Combination (MeSH), Female (MeSH), Humans (MeSH), Iron Chelating Agents (therapeutic use), Male (MeSH), Middle Aged (MeSH), Off-Label Use (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (virology), Respiration, Artificial (MeSH), Retrospective Studies (MeSH), Romania (MeSH), SARS-CoV-2 (MeSH).
- MESH :
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Deferasirox, Iron Chelating Agents.
- geographic : Romania.
- drug therapy : COVID-19, Cytokine Release Syndrome, Pneumonia, Viral.
- virology : Pneumonia, Viral.
- Adult, Aged, Aged, 80 and over, Comorbidity, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Off-Label Use, Respiration, Artificial, Retrospective Studies, SARS-CoV-2.
Abstract
ABSTRACT
Tocilizumab (TCZ), a monoclonal recombinant antibody against IL-6 receptor, is currently used in managing the cytokine release syndrome (CRS) that occurred in coronavirus disease 2019 (COVID-19) selected cases. The primary objective of our study was to establish the effectiveness of TCZ in patients with severe or critical severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pneumonia.We retrospectively analyzed 25 consecutive patients, admitted in the Academic Emergency Hospital Sibiu, Romania from April 1, 2020 until May 25, 2020, all with confirmed SARS-CoV-2 infection and severe pneumonia. All patients were treated off-label with TCZ, beside their standard care. Adjuvant iron chelator was associated in 11 patients.Six female and 19 male patients admitted in our hospital all with confirmed SARS-CoV-2 infection and severe pneumonia as defined by Chinese Centers for Disease Control and Prevention were enrolled in this study. Seventeen of the 25 enrolled patients (68%) were seriously ill requiring noninvasive ventilation or oxygen mask, and 8 cases (32%) were critically ill requiring invasive mechanical ventilation. All patients received TCZ, and also received hydroxychloroquine, and lopinavir/ritonavir 200/50 mg for 10 days. Adjuvant iron chelator (deferasirox - marketed as Exjade) was associated in 11 patients who had ferritin serum levels above 1000 ng/mL. No side effects were encountered during infusions or after TCZ. We observed a rapid increase in arterial oxygen saturation for 20 of the 25 cases (80%) with a favorable evolution toward healing. Survivors were younger than 60 years old (80%), had less comorbidities (10% no comorbidities, 70% with 1 or 2 comorbidities), lower serum ferritin levels (30% under 1000 ng/mL), and 50% had no serum glucose elevation. Our patients with CRS had no response to corticosteroid therapy. Five out of the 25 patients had an unfavorable evolution to death. The off-label use of TCZ in patients with severe or critically ill form of SARS-CoV-2 infection had good results in our study.Off-label use of TCZ in severe and critical cases of COVID-19 pneumonia is effective in managing the "cytokine storm." Better outcomes were noted in younger patients. Associated adjuvant iron chelators may contribute to a good outcome and needs to be confirmed in larger studies.
DOI: 10.1097/MD.0000000000025832
PubMed: 33950993
PubMed Central: PMC8104262
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.</title>
<author><name sortKey="Birlutiu, Victoria" sort="Birlutiu, Victoria" uniqKey="Birlutiu V" first="Victoria" last="Birlutiu">Victoria Birlutiu</name>
<affiliation><nlm:affiliation>Lucian Blaga University of Sibiu, Faculty of Medicine Sibiu, Academic Emergency Hospital Sibiu - Infectious Diseases Clinic, Sibiu.</nlm:affiliation>
<wicri:noCountry code="subField">Sibiu</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Birlutiu, Rares Mircea" sort="Birlutiu, Rares Mircea" uniqKey="Birlutiu R" first="Rares Mircea" last="Birlutiu">Rares Mircea Birlutiu</name>
<affiliation><nlm:affiliation>Lucian Blaga University of Sibiu, Faculty of Medicine Sibiu, FOISOR Clinical Hospital of Orthopedics, Traumatology, and Osteoarticular TB Bucharest.</nlm:affiliation>
<wicri:noCountry code="subField">and Osteoarticular TB Bucharest</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Chicea, Liana" sort="Chicea, Liana" uniqKey="Chicea L" first="Liana" last="Chicea">Liana Chicea</name>
<affiliation wicri:level="1"><nlm:affiliation>Lucian Blaga University of Sibiu, Faculty of Medicine Sibiu, Academic Emergency Hospital Sibiu - Internal Medicine Clinic, Sibiu, Romania.</nlm:affiliation>
<country xml:lang="fr">Roumanie</country>
<wicri:regionArea>Lucian Blaga University of Sibiu, Faculty of Medicine Sibiu, Academic Emergency Hospital Sibiu - Internal Medicine Clinic, Sibiu</wicri:regionArea>
<wicri:noRegion>Sibiu</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33950993</idno>
<idno type="pmid">33950993</idno>
<idno type="doi">10.1097/MD.0000000000025832</idno>
<idno type="pmc">PMC8104262</idno>
<idno type="wicri:Area/Main/Corpus">000051</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000051</idno>
<idno type="wicri:Area/Main/Curation">000051</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000051</idno>
<idno type="wicri:Area/Main/Exploration">000051</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.</title>
<author><name sortKey="Birlutiu, Victoria" sort="Birlutiu, Victoria" uniqKey="Birlutiu V" first="Victoria" last="Birlutiu">Victoria Birlutiu</name>
<affiliation><nlm:affiliation>Lucian Blaga University of Sibiu, Faculty of Medicine Sibiu, Academic Emergency Hospital Sibiu - Infectious Diseases Clinic, Sibiu.</nlm:affiliation>
<wicri:noCountry code="subField">Sibiu</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Birlutiu, Rares Mircea" sort="Birlutiu, Rares Mircea" uniqKey="Birlutiu R" first="Rares Mircea" last="Birlutiu">Rares Mircea Birlutiu</name>
<affiliation><nlm:affiliation>Lucian Blaga University of Sibiu, Faculty of Medicine Sibiu, FOISOR Clinical Hospital of Orthopedics, Traumatology, and Osteoarticular TB Bucharest.</nlm:affiliation>
<wicri:noCountry code="subField">and Osteoarticular TB Bucharest</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Chicea, Liana" sort="Chicea, Liana" uniqKey="Chicea L" first="Liana" last="Chicea">Liana Chicea</name>
<affiliation wicri:level="1"><nlm:affiliation>Lucian Blaga University of Sibiu, Faculty of Medicine Sibiu, Academic Emergency Hospital Sibiu - Internal Medicine Clinic, Sibiu, Romania.</nlm:affiliation>
<country xml:lang="fr">Roumanie</country>
<wicri:regionArea>Lucian Blaga University of Sibiu, Faculty of Medicine Sibiu, Academic Emergency Hospital Sibiu - Internal Medicine Clinic, Sibiu</wicri:regionArea>
<wicri:noRegion>Sibiu</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Medicine</title>
<idno type="eISSN">1536-5964</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Antibodies, Monoclonal, Humanized (therapeutic use)</term>
<term>COVID-19 (drug therapy)</term>
<term>Comorbidity (MeSH)</term>
<term>Cytokine Release Syndrome (drug therapy)</term>
<term>Deferasirox (therapeutic use)</term>
<term>Drug Therapy, Combination (MeSH)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Iron Chelating Agents (therapeutic use)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Off-Label Use (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Respiration, Artificial (MeSH)</term>
<term>Retrospective Studies (MeSH)</term>
<term>Romania (MeSH)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Agents chélateurs du fer (usage thérapeutique)</term>
<term>Anticorps monoclonaux humanisés (usage thérapeutique)</term>
<term>Association de médicaments (MeSH)</term>
<term>Comorbidité (MeSH)</term>
<term>Déférasirox (usage thérapeutique)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Roumanie (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Utilisation hors indication (MeSH)</term>
<term>Ventilation artificielle (MeSH)</term>
<term>Études rétrospectives (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term>
<term>Deferasirox</term>
<term>Iron Chelating Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Romania</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
<term>Cytokine Release Syndrome</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents chélateurs du fer</term>
<term>Anticorps monoclonaux humanisés</term>
<term>Déférasirox</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Comorbidity</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Off-Label Use</term>
<term>Respiration, Artificial</term>
<term>Retrospective Studies</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Association de médicaments</term>
<term>Comorbidité</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Roumanie</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Utilisation hors indication</term>
<term>Ventilation artificielle</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Roumanie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>ABSTRACT</b>
</p>
<p>Tocilizumab (TCZ), a monoclonal recombinant antibody against IL-6 receptor, is currently used in managing the cytokine release syndrome (CRS) that occurred in coronavirus disease 2019 (COVID-19) selected cases. The primary objective of our study was to establish the effectiveness of TCZ in patients with severe or critical severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pneumonia.We retrospectively analyzed 25 consecutive patients, admitted in the Academic Emergency Hospital Sibiu, Romania from April 1, 2020 until May 25, 2020, all with confirmed SARS-CoV-2 infection and severe pneumonia. All patients were treated off-label with TCZ, beside their standard care. Adjuvant iron chelator was associated in 11 patients.Six female and 19 male patients admitted in our hospital all with confirmed SARS-CoV-2 infection and severe pneumonia as defined by Chinese Centers for Disease Control and Prevention were enrolled in this study. Seventeen of the 25 enrolled patients (68%) were seriously ill requiring noninvasive ventilation or oxygen mask, and 8 cases (32%) were critically ill requiring invasive mechanical ventilation. All patients received TCZ, and also received hydroxychloroquine, and lopinavir/ritonavir 200/50 mg for 10 days. Adjuvant iron chelator (deferasirox - marketed as Exjade) was associated in 11 patients who had ferritin serum levels above 1000 ng/mL. No side effects were encountered during infusions or after TCZ. We observed a rapid increase in arterial oxygen saturation for 20 of the 25 cases (80%) with a favorable evolution toward healing. Survivors were younger than 60 years old (80%), had less comorbidities (10% no comorbidities, 70% with 1 or 2 comorbidities), lower serum ferritin levels (30% under 1000 ng/mL), and 50% had no serum glucose elevation. Our patients with CRS had no response to corticosteroid therapy. Five out of the 25 patients had an unfavorable evolution to death. The off-label use of TCZ in patients with severe or critically ill form of SARS-CoV-2 infection had good results in our study.Off-label use of TCZ in severe and critical cases of COVID-19 pneumonia is effective in managing the "cytokine storm." Better outcomes were noted in younger patients. Associated adjuvant iron chelators may contribute to a good outcome and needs to be confirmed in larger studies.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33950993</PMID>
<DateCompleted><Year>2021</Year>
<Month>05</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>05</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>100</Volume>
<Issue>18</Issue>
<PubDate><Year>2021</Year>
<Month>May</Month>
<Day>07</Day>
</PubDate>
</JournalIssue>
<Title>Medicine</Title>
<ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
</Journal>
<ArticleTitle>Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.</ArticleTitle>
<Pagination><MedlinePgn>e25832</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000025832</ELocationID>
<Abstract><AbstractText Label="ABSTRACT" NlmCategory="UNASSIGNED">Tocilizumab (TCZ), a monoclonal recombinant antibody against IL-6 receptor, is currently used in managing the cytokine release syndrome (CRS) that occurred in coronavirus disease 2019 (COVID-19) selected cases. The primary objective of our study was to establish the effectiveness of TCZ in patients with severe or critical severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pneumonia.We retrospectively analyzed 25 consecutive patients, admitted in the Academic Emergency Hospital Sibiu, Romania from April 1, 2020 until May 25, 2020, all with confirmed SARS-CoV-2 infection and severe pneumonia. All patients were treated off-label with TCZ, beside their standard care. Adjuvant iron chelator was associated in 11 patients.Six female and 19 male patients admitted in our hospital all with confirmed SARS-CoV-2 infection and severe pneumonia as defined by Chinese Centers for Disease Control and Prevention were enrolled in this study. Seventeen of the 25 enrolled patients (68%) were seriously ill requiring noninvasive ventilation or oxygen mask, and 8 cases (32%) were critically ill requiring invasive mechanical ventilation. All patients received TCZ, and also received hydroxychloroquine, and lopinavir/ritonavir 200/50 mg for 10 days. Adjuvant iron chelator (deferasirox - marketed as Exjade) was associated in 11 patients who had ferritin serum levels above 1000 ng/mL. No side effects were encountered during infusions or after TCZ. We observed a rapid increase in arterial oxygen saturation for 20 of the 25 cases (80%) with a favorable evolution toward healing. Survivors were younger than 60 years old (80%), had less comorbidities (10% no comorbidities, 70% with 1 or 2 comorbidities), lower serum ferritin levels (30% under 1000 ng/mL), and 50% had no serum glucose elevation. Our patients with CRS had no response to corticosteroid therapy. Five out of the 25 patients had an unfavorable evolution to death. The off-label use of TCZ in patients with severe or critically ill form of SARS-CoV-2 infection had good results in our study.Off-label use of TCZ in severe and critical cases of COVID-19 pneumonia is effective in managing the "cytokine storm." Better outcomes were noted in younger patients. Associated adjuvant iron chelators may contribute to a good outcome and needs to be confirmed in larger studies.</AbstractText>
<CopyrightInformation>Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Birlutiu</LastName>
<ForeName>Victoria</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Lucian Blaga University of Sibiu, Faculty of Medicine Sibiu, Academic Emergency Hospital Sibiu - Infectious Diseases Clinic, Sibiu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Birlutiu</LastName>
<ForeName>Rares Mircea</ForeName>
<Initials>RM</Initials>
<Identifier Source="ORCID">0000-0001-7400-2904</Identifier>
<AffiliationInfo><Affiliation>Lucian Blaga University of Sibiu, Faculty of Medicine Sibiu, FOISOR Clinical Hospital of Orthopedics, Traumatology, and Osteoarticular TB Bucharest.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chicea</LastName>
<ForeName>Liana</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Lucian Blaga University of Sibiu, Faculty of Medicine Sibiu, Academic Emergency Hospital Sibiu - Internal Medicine Clinic, Sibiu, Romania.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>LBUS-IRG-2020-06</GrantID>
<Agency>Lucian Blaga University of Sibiu & Hasso Plattner Foundation</Agency>
<Country></Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Medicine (Baltimore)</MedlineTA>
<NlmUniqueID>2985248R</NlmUniqueID>
<ISSNLinking>0025-7974</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007502">Iron Chelating Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>I031V2H011</RegistryNumber>
<NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>V8G4MOF2V9</RegistryNumber>
<NameOfSubstance UI="D000077588">Deferasirox</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000077588" MajorTopicYN="N">Deferasirox</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007502" MajorTopicYN="N">Iron Chelating Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D056687" MajorTopicYN="N">Off-Label Use</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012383" MajorTopicYN="N" Type="Geographic">Romania</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>The authors declare no conflicts of interest.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>07</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2021</Year>
<Month>03</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2021</Year>
<Month>5</Month>
<Day>5</Day>
<Hour>17</Hour>
<Minute>42</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2021</Year>
<Month>5</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>5</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33950993</ArticleId>
<ArticleId IdType="doi">10.1097/MD.0000000000025832</ArticleId>
<ArticleId IdType="pii">00005792-202105070-00081</ArticleId>
<ArticleId IdType="pmc">PMC8104262</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Autoimmun Rev. 2020 Jul;19(7):102568</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32376398</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 Jun;26(6):842-844</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32398875</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncologist. 2018 Aug;23(8):943-947</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29622697</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem. 2020 Mar 1;28(5):115327</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31992476</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Biol Ther. 2020 Jul;20(7):717-723</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32406282</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Rheumatol. 2018 Sep;30(5):514-520</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29870499</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Immunopathol. 2017 Jul;39(5):529-539</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28466096</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Intern Med. 2020 Jun;76:31-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32405160</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2020 Aug;129:104444</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32570043</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Transl Med. 2020 Apr 14;18(1):164</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32290839</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chest. 2020 Jul;158(1):e15-e19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32343968</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Drug Investig. 2020 Jun;40(6):511-518</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32337664</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Germs. 2020 Mar 2;10(1):8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32274354</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 7;323(13):1239-1242</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2018 Feb 1;378(5):439-448</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29385370</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):420-422</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32085846</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Oct;92(10):2042-2049</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32369191</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cytokine X. 2020 Jun;2(2):100029</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32421092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Clin Microbiol Rep. 2020 Apr 20;:1-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32318324</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Jun;80(6):607-613</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32283152</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32350134</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Host Microbe. 2020 Mar 11;27(3):325-328</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32035028</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 Sep-Oct;37:101685</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32334088</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1033-1034</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32192578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Microbiol. 2013 Oct;21(10):544-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23770275</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29161116</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2018 Jan;149:58-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29128390</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Roumanie</li>
</country>
</list>
<tree><noCountry><name sortKey="Birlutiu, Rares Mircea" sort="Birlutiu, Rares Mircea" uniqKey="Birlutiu R" first="Rares Mircea" last="Birlutiu">Rares Mircea Birlutiu</name>
<name sortKey="Birlutiu, Victoria" sort="Birlutiu, Victoria" uniqKey="Birlutiu V" first="Victoria" last="Birlutiu">Victoria Birlutiu</name>
</noCountry>
<country name="Roumanie"><noRegion><name sortKey="Chicea, Liana" sort="Chicea, Liana" uniqKey="Chicea L" first="Liana" last="Chicea">Liana Chicea</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000296 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000296 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:33950993 |texte= Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33950993" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
This area was generated with Dilib version V0.6.38. |